Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor, escorting it to its destruction in the lysosome and thereby preventing the recirculation of the low-density lipoprotein receptor to the hepatocyte cell surface. Both gain-of-function mutations in PCSK9 (causing marked increases in low-density lipoprotein cholesterol [LDL-C] concentration and premature atherosclerosis) and loss-of-function mutations (causing modest LDL-C reduction with low rates of coronary heart disease) have been described. Several monoclonal antibodies to PCSK9 have achieved LDL-C reductions of 50% to 70% across various patient populations and background lipid therapies. Phase 2/3 trials have demonstrated good tolerability without clear drug-related toxicity, although the number and duration of patients treated to date is modest. Currently, 4 phase 3 trials involving >70,000 patients are testing whether these drugs reduce cardiovascular events. The U.S. Food and Drug Administration is currently reviewing the existing data to determine whether these agents could be made available prior to the completion of these cardiovascular endpoint trials expected in 2018. (J Am Coll Cardiol 2015;65:2638-51) © 2015 by the American College of Cardiology Foundation. T wo separate lines of research-the first exploring the structure and function of a family of serine proteases, known as proprotein convertases, that activate a wide variety of proteins regulating several key cellular pathways in humans and other organisms (1), and the second investigating genetic causes of familial hypercholesterolemia (FH) (2), were the parents of a potent new class of low-density lipoprotein cholesterol (LDL-C)lowering drugs known as the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In 2001, scientists at Millennium Pharmaceuticals discovered PCSK9 during studies of cerebellar neuron apoptosis, and the gene was characterized shortly thereafter, in 2003 (3). In parallel, research by the French Network for Autosomal Dominant Hypercholesterolemia (4), and independently in Utah (5), identified a third FH locus (the first 2 mutation loci map to the lowdensity lipoprotein receptor [LDL-R] and apolipoprotein B genes). In 2003, Abifadel et al. (6) were the first to describe mutations in the PCSK9 gene as a cause of FH. Studies in families from Utah (7), Norway (8), and the United Kingdom (9) provided confirmation that PCSK9 mutations were responsible for FH.
from the development of coronary heart disease (CHD) (11) . Thus, the stage was set for the development of therapies that could inhibit PCSK9, lower LDL-C, and, hopefully, reduce atherothrombotic events.
ROLE OF PCSK9 IN REGULATING

LDL-R METABOLISM
The principal route of clearance of circulating LDL-C from the blood is via hepatocyte endocytosis-a process mediated by binding of LDL-C to LDL-Rs on the hepatocyte cell membrane (Central Illustration).
The typical LDL-R is able to recirculate back to the cell surface up to 150 times, with PCSK9 playing a critical role in LDL-R metabolism. The catalytic subunit of PCSK9 binds to the epidermal growth factor-like domain of the LDL-R and then escorts the receptor to its degradation within the lysosome.
Given the counter-regulatory role played by PCSK9, gain-of-function mutations in PCSK9 resulting in its overexpression lead to fewer functioning LDL-Rs and higher levels of circulating LDL-C. Conversely, lossof-function mutations in PCSK9 result in lower LDL-C levels. PCSK9 can bind other proteins; appears to play additional, lesser roles in lipid metabolism; and its expression can be modified by a number of factors (e.g., statins increase PCSK9 levels)-further details can be found elsewhere (1, 2) .
THERAPEUTIC INHIBITION OF PCSK9
Studies in PCSK9 knockout mice demonstrated a 2-to 3-fold increase in LDL-Rs and a 25% to 50% decrease in circulating cholesterol (12) . This led to the exploration of a number of methods to reduce PCSK9 levels and/or inhibit its function, including both oral and parenteral therapies (2) (Central Illustration). Both antisense oligonucleotides and small interfering ribonucleic acids have been studied in pre-clinical and phase 1 human studies. Mimetic peptides, LDL-R antagonists, small molecules, and gene silencing approaches to modulate PCSK9 are in earlier stages of development. A number of approaches using novel small molecules have been described, including the use of epidermal growth factor-A mimetics to block PCSK9 binding of the LDL-R (13) and inhibitors of pro-PCSK9 autoprocessing and/or secretion (14) ; unfortunately, the PCSK9-LDL-R complex has a relatively flat surface that makes binding by a small molecule inhibitor challenging (15) . However, parenteral monoclonal antibodies (MoAbs) have been the most successful strategy to date and are now in late-stage (phase 3 clinical trials) testing ( Table 1) ; thus, they are the focus of this paper.
PCSK MONOCLONAL ANTIBODIES
The first studies in humans in healthy volunteers (16, 17) were conducted with the fully human PCSK9 MoAb REGN727 (hereafter alirocumab) and, shortly thereafter, with the fully human MoAb AMG145 (evolocumab [18] ) and the humanized MoAb RN316 (bococizumab [19] ). These studies demonstrated dosedependent reductions in unbound PCSK9 levels beginning within hours after injection with top doses achieving unmeasurable PCSK9 levels for 2 weeks before returning to baseline >6 weeks following a single injection. Dose-dependent reduction in LDL-C (up to 70%), timing of nadir LDL-C (between 4 and 14 days), and delay in return to baseline LDL-C (2 to 8þ weeks) were observed with each of these MoAbs. More recently, data were presented with LY3015014, a humanized MoAb with a unique epitope that permits the normal proteolytic degradation of PCSK9 (unlike other MoAbs), thereby resulting in a more sustained lowering of LDL-C (20) .
PHASE 2 CLINICAL TRIALS
Both alirocumab and evolocumab have been extensively evaluated in more than a dozen phase 2 trials exploring dose ranging and dose frequency, various patient populations, and adjunctive lipid-lowering therapies, with fewer studies available with bococizumab ( Table 2 ). The top doses being developed of alirocumab (150 mg subcutaneously [SC] every 2 weeks) and evolocumab (140 mg SC every 2 weeks; 420 mg SC every 4 weeks) administered for 12 weeks reduce LDL-C by approximately 60% to 70% (75 to 85 mg/dl) at trough (17,18) and >90% (>100 mg/dl) at peak (21) . The vast majority (70% to 90%) of patients with hyperlipidemia treated with statin therapy were able to achieve an LDL-C <70 mg/dl with alirocumab (22) and evolocumab (23, 24) , demonstrating the ability of these drugs to drive down levels of LDL-C to ranges not possible with existing therapies. A phase 2 trial with bococizumab in 351 patients with hypercholesterolemia reported LDL-C reductions of 53% (53 mg/dl) with 150 mg every 2 weeks and by 41% (45 mg/dl) with 300 mg every 4 weeks, adjusted for placebo (19) . A phase 2 trial comparing LY3015014 with placebo in 527 patients with hypercholesterolemia treated with standard care (including statins) revealed reductions in LDL-C of up to 58% (w79 mg/dl) and 45% (w61 mg/dl) with administration every 4 and 8 weeks, respectively, adjusted for placebo (25) . In phase 2 studies, LDL-C was significantly and similarly lowered with alirocumab and evolocumab compared with placebo, whether patients were taking no, low-dose, or high-dose statins; taking ezetimibe; or had heterozygous FH. The findings appear consistent across major subgroups (e.g., age, sex, diabetes, risk level) with no significant treatment-subgroup interactions consistently reported. Longer-term follow-up ($1 year) demonstrated a persistent similar reduction in LDL-C as was observed in the 12-week studies.
In addition, evolocumab reduced LDL-C in the majority of patients with homozygous FH (26, 27) ; the responders had partially functioning (2% to 25%) LDL-R. Genetic analyses in patients who did not respond to evolocumab demonstrated nonfunctioning LDL-Rs (<2% function) (26 SREBP-2 in hepatocytes regulates transcription of several lipids and proteins, including the low-density lipoprotein receptor (LDL-R) and proprotein convertase subtilisin/kexin type 9 (PCSK9) (step 1). PCSK9 is processed in the endoplasmic reticulum into a mature form (step 2) and undergoes packaging by the Golgi apparatus (as does the LDL-R) before being secreted (step 3). The LDL-R binds circulating low-density lipoprotein cholesterol (LDL-C) (step 4), and the pair is internalized in endosomes, where LDL-C can be shuttled for other use. Meanwhile, the LDL-R recirculates to the cell surface (step 5) up to 150 times, removing additional LDL-C from the circulation. PCSK9 regulates the number of LDL-R by binding to and internalizing the LDL-R (step 6), escorting it to its destruction in the lysosome (step 7). This does not permit the LDL-R to recirculate. Several methods to interfere with the function of PCSK9 are shown by the letters within red octagons. Small interfering ribonucleic acids (siRNAs) (A) can block transcription of PCSK9 messenger ribonucleic acid, whereas small molecular inhibitors (B) can disrupt the processing of PCSK9-both approaches reduce the production of functional PCSK9. Two extracellular approaches to inhibit PCSK9 function include monoclonal antibodies (MoAbs) (C) and adnectins (D) that prevent binding of PCSK9 to the LDL-R. SREBP ¼ sterol-binding regulatory element-binding transcription factor. Table 3) . (36, 37) . In 614 patients with baseline LDL-C 100 to 190 mg/dl, evolocumab reduced LDL-C at 12 weeks by 55% to 57% (w80 mg/dl) on average compared with placebo, whereas ezetimibe achieved an 18% to 19% (w26 mg/dl) reduction (36) . Similarly, in a study of alirocumab monotherapy versus ezetimibe in 103 patients with a 1% to 5% 10-year risk of fatal cardiovascular events, alirocumab reduced LDL-C by 47% (66 mg/dl) at 24 weeks, compared with only 16% (22 mg/dl) for ezetimibe (37) . COMBINATION WITH STATIN. In 316 patients with established CHD or CHD risk equivalents and hypercholesterolemia, alirocumab reduced LDL-C at 24 weeks by 46% (46 mg/dl) more than placebo, with 75% of patients achieving an LDL-C <70 mg/dl (compared with 9% with placebo) (38). In a similar population of patients who were taking maximally tolerated statins, alirocumab reduced LDL-C by 30% (31 mg/dl) more than ezetimibe, permitted more patients to achieve an LDL-C <70 mg/dl than ezetimibe (77% vs. 46%), and had a similar safety profile to ezetimibe (39).
Giugliano and Sabatine
Evolocumab was compared with placebo and with ezetimibe in 2,067 patients with an LDL-C $150 mg/dl, all of whom were treated with either moderate or intensive statin therapy (40). For patients on a highintensity statin (atorvastatin 80 mg or rosuvastatin 40 mg), evolocumab reduced the mean LDL-C compared with placebo at 10 and 12 weeks by 66% to 75% (56 to 70 mg/dl) with 140 mg every 2 weeks and by 63% to 75% (51 to 66 mg/dl) with 420 mg every 4 weeks. In patients receiving moderate-dose statins Evolocumab 420 mg every 4 weeks reduced the average LDL-C by 61% from 120 to 48 mg/dl at 12 weeks. Adverse events (the primary study endpoint) occurred in 69% of patients treated with evolocumab versus 65% in the SOC group, with no difference in the rate of serious adverse events (7.5% in each group Event Rate (%) Whether the safety and tolerability profile of the PCSK9 MoAbs will continue to be as favorable as reported in the phase 2 and early phase 3 studies remains to be seen. However, their introduction into clinical practice could result in a major shift in the LDL-C population distribution (Figure 3 ) and has the potential to have a large effect on future atheroembolic events. As seen in the Mendelian randomization studies of loss-of-function mutations Although event rates in a primary prevention population are considerably lower than in secondary pre- 
